These results confirm and extend previous retrospective results indicating that children with ADHD are at high risk of developing a wide range of impairments affecting multiple domains of psychopathology such as cognition, interpersonal, school, and family functioning. These findings provide further support for the value of considering psychiatric comorbidity in both clinical assessment and research protocols involving children with ADHD.

No abstract

This study, an expansion of an earlier study of parenting behaviors of anxious mothers, examined the relationship of both mother and child anxiety disorders to mother behavior in parent--child interactions. Participants were 68 mother--child dyads with children ranging in age from 7 to 15 years. Mothers and children completed diagnostic evaluations and engaged in conversational tasks; behaviors were rated by coders who were blind to diagnosis. Mothers of anxious children, regardless of their own anxiety, were less warm (p <.05) toward their children. They also granted less autonomy (p <.01). There was an interaction between mother and child anxiety in predicting maternal catastrophizing (p <.01), with anxious mothers and nonanxious mothers of anxious children likely to catastrophize. Theoretical and research implications are discussed.

Objective-To identify predictors and moderators of outcome in the first Pediatric OCD Treatment Study (POTS I) among youth (N=112) randomly assigned to sertraline, cognitive behavioral therapy (CBT), both sertraline and CBT (COMB), or a pill placebo.Method-Potential baseline predictors and moderators were identified by literature review. The outcome measure was an adjusted week 12 predicted score for the Children's Yale Brown Obsessive Compulsive Scale (CY-BOCS). Main and interactive effects of treatment condition and each Correspondence to: Dr. Abbe Garcia, Bradley/Hasbro Children's Research Center, 1 Hoppin St, Providence, RI 02903; Abbe_Garcia@Brown.edu. Disclosure: Dr. Garcia receives research support from the National Institute of Mental Health. Dr. Freeman receives research support from the National Institute of Mental Health. Dr. Franklin receives research support from the National Institute of Mental Health. Dr. March receives research support from Eli Lilly and Co., Pfizer, the National Institute of Mental Health, and the National Alliance for Research on Schizophrenia and Depression. He has served as a consultant or scientific advisory for Bristol-Myers Squibb, Eli Lilly and Co., Johnson and Johnson, MedAvente, Pfizer, Scion, Psymetrix, and Vivus. He is a stockholder of MedAvante. He receives royalties from MultiHealth Systems, Guilford Press, and Oxford University Press. Dr. Foa receives research support from Pfizer, Solvay, Eli Lilly and Co., SmithKline Beecham, GlaxoSmithKline, Cephalon, Bristol-Myers Squibb, Forest, Ciba Geigy, Kalo-Duphar, and the American Psychiatric Association. She has served as a speaker for Pfizer, GlaxoSmithKline, Forest Pharmaceuticals, the American Psychiatric Association, and Jazz Pharmaceuticals. She has served as a consultant for Acetelion Pharmaceuticals. Drs. Sapyta and Moore report no biomedical financial interests or potential conflicts of interest. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. candidate predictor or moderator variable were examined using GLM on the adjusted predicted week 12 CY-BOCS scores. Clinical Trials Registration Information NIH Public AccessResults-Youth with lower OCD severity, less OCD-related functional impairment, greater insight, fewer comorbid externalizing symptoms, and lower levels of family accommodation showed greater improvement across treatment conditions than their counterparts after acute POTS treatment. Those with a family history of OCD had a six-fold decrease in effect size in CBT monotherapy relative to their counterparts in CBT without a family history of OCD.Conclusions-G...

No abstract